Enolase inhibition alters metabolic hormones and inflammatory factors to promote neuroprotection in spinal cord injury.
Ontology highlight
ABSTRACT: Enolase inhibition is a potential therapeutic strategy currently being investigated for treatment of spinal cord injury (SCI) as it reduces pro-inflammatory cytokines and chemokines, alters metabolic factors, and reduces gliosis in acute SCI. Herein, the role of enolase in SCI has been examined to better understand the effects of this enzyme on inflammation, metabolic hormones, glial cell activation, and neuroprotection under these shorter injury conditions. Immunohistochemical analyses of inflammatory markers vimentin, Cox-2, and caspase-1 indicated that enolase inhibition attenuated the elevated levels of inflammation seen following SCI. Iba1, GFAP, NFP, and CSPG staining indicated that enolase inhibition with prolonged administration of ENOblock reduced microglia/astrocyte activation an
SUBMITTER: Polcyn R
PROVIDER: S-EPMC7483987 | biostudies-literature | 2020 Oct
REPOSITORIES: biostudies-literature
ACCESS DATA